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Abstract
Background: An association between resting heart rate (RHR) and cardiovascular morbidity 
and mortality has been shown in patients with coronary artery disease (CAD). We aimed to 
evaluate the RHR and its relationship with clinical variables in outpatients with stable CAD 
at secondary and tertiary care centers in Turkey.
Methods: Adults with stable CAD in sinus rhythm were included in this non-interventional, 
national, cross-sectional, multicenter study. Data were collected at a single study visit from  
83 centers.
Results: The mean ± standard deviation age of all patients (n = 2,919) was 61 ± 10 years 
and 73% were males. The mean (SD) RHR was 73 ± 12 bpm, and 62% of patients had RHR 
of ≥ 70 bpm. Females more frequently had RHR ≥ 70 bpm compared with males (67% vs. 
60%; p = 0.002). RHR was significantly higher in patients with angina than in those without 
(76 ± 13 vs. 73 ± 11 bpm, p < 0.001). Left ventricular ejection fraction and heart rate lower-
ing drug use were significantly lower in patients with a RHR ≥ 70 bpm (p < 0.05).
Conclusions: The RHR of outpatients with stable CAD was not within the level recommended 
by the guidelines. (Cardiol J 2014; 21, 4: 378–383)
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Introduction
Epidemiological studies have demonstrated 
the importance of resting heart rate (RHR) in 
healthy subjects [1]. Also, an association between 
RHR and cardiovascular (CV) morbidity and mor-
tality has been shown in patients with CV disease 
[2–6]. A recent study showed that lowering RHR 
decreased the CV mortality in coronary artery 
disease (CAD) patients [7, 8]. RHR has also been 
integrated into the risk assessment in acute coro-
nary syndrome (ACS) [9]. Although a great number 
of studies have shown that RHR is a predictor of 
total and CV mortality independent of other risk 
factors, there is no data regarding the RHR in 
outpatients with stable CAD in Turkey.
This study aimed at evaluating RHR, clinical 
variables influencing RHR, the use of heart rate 
(HR)-lowering drugs in outpatients with stable 
CAD in Turkey.
Methods
The PULSE Study was a non-interventional, 
national, cross-sectional, multicenter study con-
ducted by 86 cardiologists at 83 secondary and 
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tertiary healthcare centers in Turkey, between 
February and July 2011. The study population 
comprised 2,919 adult outpatients with stable CAD 
in sinus rhythm, as verified with standard 12-lead 
electrocardiography (ECG).
Patients with a history of ACS, or who un-
derwent coronary revascularization more than 
3 months prior, or angiographic evidence of coronary 
stenosis of at least 50% of one of the major arteries, 
were included in the study.
Patients hospitalized for CV disease within the 
preceding 3 months, and patients with advanced heart 
failure, a permanent pacemaker, sick sinus syndrome, 
sinoatrial block, total atrioventricular block, atrial 
fibrillation (AF), severe kidney or liver disease, se - 
condary angina, and pregnant or breast-feeding women 
were excluded from the study. Written informed 
consent was obtained from all the participants.
Data on patient demographics, medical history 
of CAD, angina, concomitant diseases, physical 
examination, anthropometric measurements, labo-
ratory tests, RHR, and HR-lowering medications 
were collected at a single study visit. In the morn-
ing hours, RHR was determined by ECG performed 
after resting for 10 min. Laboratory tests and 
echocardiographic examination were performed 
within 3 months before the inclusion visit.
Data were collected using a standardized case 
report form, and were sent electronically to the data 
management center where checks for completeness, 
internal consistency, and accuracy were run.
Statistical analyses
Statistical analyses were performed using 
computer software (SPSS version 17.0, SPSS Inc. 
Chicago, IL, USA). Fisher’s exact and c2 tests were 
used for the comparison of categorical data, while 
the student’s t test and Mann-Whitney U-test 
were used for the analysis of parametric variables. 
A p value < 0.05 was considered statistically 
significant.
Results
A total of 2,919 patients from 83 centers were 
included in the present study. The mean ± stan - 
dard deviation (SD) age was 61 ± 10 (min–max: 
23–90) years. The majority of the study popu-
lat ion was male (73%, p < 0.001);  37% 
(n = 1,065) of the patients had a history of ACS, 
72% (n = 2,102) had a history of percutaneous/ 
/surgical coronary revascularization, and 34% 
(n = 999) had angiographic evidence of at least 50% 
stenosis in more than one of the major coronary ar-
teries. The patients were divided into two groups ac-
cording to their RHR. Lower RHR group (n = 1,107; 
38%) had a RHR of < 70 bpm and higher RHR 
group (n = 1,812; 62%) had RHR of ≥ 70 bpm. 
If we regard 60 bpm as a threshold for the RHR 
analysis, 90% of our study population would have 
RHR > 60 bpm.
Characteristics of both groups are shown in 
Table 1. The RHR was 73 ± 12 bpm. A signifi-
cantly higher percentage of females had RHR ≥ 
≥ 70 bpm compared with males (67% vs. 60%, 
p = 0.002). The mean ± SD ages of each gender did 
not differ between RHR groups (p = 0.523). In the 
higher RHR group, females were older than males 
(62.4 ± 10.8 vs. 60.9 ± 10.1 years, p = 0.001). 
The RHR was significantly higher in patients with 
angina than in those without (76 ± 13 vs. 73 ± 11 bpm, 
p < 0.001).
In the higher RHR group, systolic and diastolic 
blood pressure, left atrial (LA) diameter, body mass 
index (BMI), body weight, and fasting blood glucose, 
total cholesterol (TC), and low density lipoprotein 
cholesterol (LDL-C) were significantly higher, 
while left ventricular ejection fraction (LVEF) and 
use of HR-lowering drugs were significantly lower 
(p < 0.05) (Table 1). With respect to HR-lowering 
medications, 70% of the population were treated 
with beta-blockers, 4% received verapamil or diltia-
zem, 1.6% ivabradine, and 0.3% digoxin (Table 1). 
Metoprolol (48.5%), carvedilol (11.6%), nebivolol 
(4.86%), bisoprolol (3.97%) were the most com-
monly used beta-blockers. In overall population 
use of survival-improving medications (antiplatelet 
drug, beta-blocker, angiotensin converting enzyme 
inhibitor [ACEI], statin) was 1,646 (56.4%) pa-
tients received antiplatelet agent(s) (acetylsalicylic 
acid: 1,520 [52.1%], other antiplatelet drugs: 274 
[9.4%]), 2,042 (70%) beta-blockers, 691 (23.7%) 
ACEI, and 939 (32.2%) statins.
A history of ACS and coronary revasculari-
zation more than 3 months prior, the presence 
of angina, any co-morbid disease particularly 
chronic obstructive pulmonary disease (COPD) 
and/or asthma, diabetes mellitus, and a low LVEF 
(< 40%) were significantly more prevalent in the 
higher RHR group (p < 0.05) (Tables 1, 2). Active 
smokers comprised 7.5% of the study population 
(Table 1). Hypertension was the most prevalent 
comorbidity (71%) (Table 2).
Discussion
According to current guidelines lowering RHR 
is an important part of CAD and heart failure treat-
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Table 1. Characteristics of the study population relative to resting heart rate.
Total population 
(n = 2919)
Lower RHR group 
(< 70 bpm)  
(n = 1107)
Higher RHR group 
(≥ 70 bpm)  
(n = 1812)
P
Age [years]* 61 ± 10 61 ± 10 61 ± 10 0.523
Males 73% 76% 71% 0.002
Females 27% 24% 29%
Weight [kg]* 80 ± 12 79 ± 12 80 ± 12 0.049
Body mass index [kg/m2]* 28 ± 4 28 ± 4 29 ± 4 0.024
Waist circumference [cm]* 95 ± 12 95 ± 12 95 ± 13 0.790
Resting heart rate [bpm]* 73 ± 12 61 ± 5 80 ± 9 < 0.001
Systolic BP [mm Hg]* 132 ± 19 130 ± 18 134 ± 20 < 0.001
Diastolic BP [mm Hg]* 79 ± 11 78 ± 119 80 ± 11 < 0.001
LVEF [%]* 53 ± 10 54 ± 10 52 ± 11 < 0.001
LVEF < 40% 12% 10% 14% 0.003
LVEF ≥ 40% 88% 90% 86%
LA diameter [cm]* 3.8 ± 0.6 3.8 ± 0.6 3.9 ± 0.5 0.007
Fasting blood glucose [mg]* 123 ± 54 113 ± 39 129 ± 60 < 0.001
Total cholesterol [mg/dL]* 187 ± 47 185 ± 51 188 ± 45 0.018
Triglycerides [mg/dL]* 155 ± 87 163 ± 86 167 ± 87 0.163
LDL cholesterol [mg/dL]* 118 ± 43 116 ± 44 119 ± 42 0.010
HDL cholesterol [mg/dL]* 43 ± 12 43 ± 13 43 ± 12 0.466
Smoking status:
Current smoker 7.5% 7.9% 7.2% 0.524
Occasional smoker 1.6% 1.8% 1.5%
Former smoker 60% 60% 59%
Never smoker 31% 30% 32%
Cigarette consumption 13 ± 24 13 ± 22 13 ± 24 0.082
(package-year)*
Heart rate lowering drug use: 75% 79% 72% < 0.001
Beta-blockers 70% 75.5% 66.6% < 0.001
Verapamil or diltiazem 4.0% 3.5% 4.2% 0.38
Ivabradine 1.6% 0.6% 2.2% 0.001
Digoxin 0.3% 0.1% 0.4% 0.166
Presence of angina 50% 45% 53% < 0.001
History of ACS 37% 32% 39% <0.001
History of CR 72% 81% 66% < 0.001
Angiographic CAD 34% 33% 35% 0.265
*These variables are expressed in mean (standard deviation); ACS — acute coronary syndrome; BP — blood pressure; CAD — coronary  
artery disease; CR — coronary revascularization (percutaneous and surgery); HDL — high density lipoprotein; LA — left atrial; LDL — low  
density lipoprotein; LVEF — left ventricular ejection fraction
Table 2. Associated co-morbidities of the study population.
Total population 
(n = 2,919)
Lower RHR group 
(< 70 bpm)  
(n = 1,107)
Higher RHR group 
(≥ 70 bpm)  
(n = 1,812)
P
All comorbidities 71% 66% 75% < 0.001
COPD and/or asthma 15% 11% 17% < 0.001
Diabetes mellitus 42% 37% 44% 0.002
Hypertension 72% 72% 72% 0.924
Heart failure 13% 12% 14% 0.185
Peripheral artery disease 2% 2.8% 1.6% 0.079
Others 28% 31% 26% 0.011
COPD — chronic obstructive pulmonary disease; RHR — resting heart rate
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ment [10, 11], and an elevated HR still remains 
a neglected CV risk factor to a large extent. Data 
on RHR obtained in routine practice show that it 
is poorly controlled [2, 3, 12–15].
According to studies that have evaluated 
healthy subjects and CAD patients, lowering 
HR improves CAD outcome in patients with 
RHR ≥ 70 bpm [1–7]. These results led to the 
suggestion that RHR ≥ 70 bpm could be used as 
a relevant threshold to stratify the risk of CV 
events in patients with CAD. In our study, 70 bpm 
was used as a threshold for the RHR analysis due 
to its prognostic value established in numerous epi-
demiologic and clinical studies. The mean RHR was 
73 bpm in our study population, and more than half 
of the patients (62%) had RHR ≥ 70 bpm. This was 
consistent with the observations of European Heart 
Survey on stable angina [3], in which the mean 
RHR was 73 bpm and 52% had RHR > 70 bpm. 
The proportion of males in our study was larger 
than females in both RHR groups, with women hav-
ing a significantly higher RHR, as shown in other 
studies [2, 14–16]. If we had regarded 60 bpm as 
the treatment goal for RHR in stable CAD patients, 
as recommended in the ACC/AHA guideline [10], it 
would not have been achieved in 90% of the entire 
study population. This rate was 72.1% in one study 
[17] and 94.5% in another study [3].
Angina was detected more frequently in pa-
tients with RHR ≥ 70 bpm. Ischemia may be 
a consequence of high RHR where myocardial 
oxygen demand will increase and coronary perfu-
sion will decrease. Surprisingly, in patients with 
RHR ≥ 70 bpm, HR-lowering drugs were under-
used. Similar results were demonstrated in other 
studies [12, 14, 17].
Sympathetic activity is increased in left ven-
tricular (LV) systolic dysfunction. Over time this 
over-activity causes decreased myocardial contrac-
tility and progressive mechanical dyssynchrony 
[18]. The importance of RHR in LV systolic dys-
function is highlighted in a study which demon-
strated that for every RHR beat increase the risk of 
a primary composite endpoint increased by 3% 
(p < 0.0001) [6]. The average LVEF in both groups was 
over 50%, whereas LVEF was lower in patients with 
RHR ≥ 70 bpm. The frequency of patients with a LVEF 
< 40% was higher in patients with RHR ≥ 70 bpm. 
This was consistent with previous studies [2, 7].
Similar rates of prior ACS in different RHR 
groups have been reported in previous studies [12, 
13]. Similar to the results of Seabra-Gomes et al. 
[14] we found a higher prevalence of prior ACS in 
patients with a higher RHR.
Patients with any co-morbid disease, par-
ticularly COPD and/or asthma, had a significantly 
higher RHR. Our finding on co-morbid disease is 
consistent with other studies [3, 14].
The autonomic nervous system has a natural 
balance between sympathetic and parasympathetic 
activities and high RHR is an indicator of sympa-
thetic over-activity [18]. Both epidemiological and 
prospective cohort studies suggest that chronic 
sympathetic over-activity, reflected as fast HR 
and high blood pressure, affects glucose tolerance 
and subsequently increases the risk of develop-
ing diabetes mellitus [19–22]. Myocardial energy 
production in diabetic patients is mostly dependent 
on non-esterified fatty acids. When compared to 
glucose oxidation, this pathway results in higher 
myocardial oxygen consumption, and in turn, this 
leads to higher RHR [19]. Our study revealed that 
high systolic and diastolic blood pressures, high 
fasting blood glucose, and evidence of diabetes 
mellitus, were more frequent in patients with 
high RHR.
BMI is a marker of general adiposity. However, 
waist circumference is an anthropometric indicator 
of central obesity and is related to visceral adiposity 
[23]. In our study, patients in higher RHR group 
had higher BMI but similar finding was not statisti-
cally confirmed for waist circumference. A previous 
study showed that waist circumference or BMI 
was significantly associated with increased RHR 
in men but not in women [24]. In another study, 
which included a high-risk population, both BMI 
and waist circumference were significantly higher 
in patients with higher RHR [20].
As our study population comprised high-risk 
patients, LDL-C and TC were higher in patients 
with RHR ≥ 70 bpm. Similar results were found 
for both LDL-C and TC in the study by Ó Hartaigh 
et al. [20]. While Vitale et al. [15] did not show any 
relationship between the RHR and TC, Okin et al. 
[21] found that higher RHR was related to high 
TC, but not to HDL-C. Steg et al. [17] reported no 
data on blood lipid levels but observed more anti-
hyperlipidemic drug use in patients with high RHR.
Abnormal LA function during adrenergic stress 
has been studied [25, 26]. LA size is largely deter-
mined by the factors influencing diastolic LV filling 
pressures [27, 28]. During tachycardia, LV filling 
and LA emptying are more compromised in patients 
with ischemia, heart failure, and hypertension than 
healthy subjects. This leads to an LA enlargement. 
LA dilatation, in the absence of organic mitral valve 
disease or AF, has been shown to reflect the burden 
of CV disease [29, 30]. In the present study, the LA 
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was larger in patients with higher RHR, however 
mean LA diameters were within normal limits in 
both groups. There are currently no reports on the 
association of LA size with RHR in patients with 
stable CAD in sinus rhythm.
Limitations of the study
While the PULSE study is the first large-scale, 
real-life data of RHR in stable CAD in Turkey, it is 
subject to limitations. The RHR inherently varies 
during the day. The RHR recorded at any particular 
time of the day may be a limitation. However, there 
are noteworthy studies which examined HR with 
a single measurement to determine stable CAD 
prognosis [1, 2, 4, 7, 13]. Inclusion of patients 
with AF could have led to error in interpretation 
of HR findings. Therefore, patients with AF were 
excluded from the study. Thus, our findings cannot 
be generalized to all stable CAD patients.
Conclusions
Reasons of inadequate control of HR in stable 
CAD patients were already well documented, and 
it has been reinforced in the Turkish population 
with this study.
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